<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03872908</url>
  </required_header>
  <id_info>
    <org_study_id>ET18-262 ELEGANT</org_study_id>
    <nct_id>NCT03872908</nct_id>
  </id_info>
  <brief_title>Satisfaction &amp; Efficacy of Compression Using Surgical Gloves in Chemo-induced Peripheral Neuropathies</brief_title>
  <acronym>ELEGANT</acronym>
  <official_title>Prospective Monocentric Study Evaluating Patients' Satisfaction and Efficacy of Compression Using Surgical Gloves in Peripheral Neuropathies Induced by Taxane or Platinum-based Chemotherapies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Leon Berard</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Leon Berard</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of Satisfaction &amp; Efficacy of Compression Using Surgical Gloves in Peripheral
      Neuropathies Due to Chemotherapy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Peripheral neuropathy (PN) is an adverse event of numerous chemotherapy agents commonly used,
      including taxanes (paclitaxel, docetaxel) and platinum-based treatments (oxaliplatine,
      cisplatine, carboplatine).

      Taxanes are widely used in breast cancer. Docetaxel and paclitaxel became indispensable
      during the last decade in metastatic and early stage breast cancer treatment. For
      platinum-based chemotherapies, oxaliplatine is one of the main molecules used in digestive
      oncology, particularly in colorectal cancer.

      The limiting toxicities of taxanes and platinum-based treatments which can lead to the
      therapeutic scheme modification (therefore to a potential diminution of efficacy and
      eventually to treatment stop) are mainly hematologic (neutropenia) and neurological, the most
      frequent neuro-toxicity event being a PN associated or not to neuropathic pains. The PN
      induced by chemotherapy can occur prematurely during the treatment course, persist between
      the treatments' cycles and last a long time after the end of cycles, with an impact on
      patients' quality of life. Symptoms are mainly sensitive, including pain, paresthesia and
      hands / foot numbness. These symptoms, as the hematologic toxicity, represent a major
      limiting factor for the treatment.

      According to the ASCO recommendations, there is no effective prophylactic method against the
      chemo-induced PN. In a retrospective study, the chilled gloves used for preventing the nail
      lesions during chemotherapy may reduce the incidence of docetaxel-induced PN. Recently, the
      surgical gloves efficacy against paclitaxel-induced PN has been evaluated prospectively in
      women presenting a metastatic or early stage breast cancer, with a percentage of grade &gt;=2 NP
      significantly lower for the hand protected by surgical gloves than the control hand without
      glove (compression-induced vasoconstriction responsible for a blood flow reduction in the
      hands and therefore for the local exposure to chemotherapy agents) and a good tolerance.

      Chilled gloves, which use the same principle of vasoconstriction through cold, are also used
      in the current practice for preventing the PN occurrence. However, contrary to surgical
      gloves, they can be not well tolerated since the very first cycles (intolerance to cold
      sensation).

      The objective of this study is to evaluate the medium and long term efficacy of compression
      induced by surgical gloves against the PN development in two frequent indications in
      oncology, patients treated with paclitaxel (breast cancer) or oxaliplatine (colorectal
      cancer) and patients' satisfaction.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 15, 2019</start_date>
  <completion_date type="Anticipated">March 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cohort1:Evaluation of patient's satisfaction when wearing surgical gloves (dominant hand) and chilled gloves (non-dominant hand) at the end of paclitaxel administration.</measure>
    <time_frame>At the end of paclitaxel administration (4 to 6 months after inclusion)</time_frame>
    <description>Global patient's satisfaction evaluated for each hand using a numeric scale from 0 (very unsatisfied) to 10 (very satisfied)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cohort 2: Efficacy of compression induced by surgical gloves vs peripheral neuropathies development in patients treated by oxaliplatine after a cumulative dose of 595 mg/m2</measure>
    <time_frame>After the end oxaliplatine administration (4 to 6 months after inclusion)</time_frame>
    <description>Percentage of NP grade &gt;= 2 after a cumulative dose of 595 mg/m2 using NCI-CTCAE v5</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cohort 1: Evaluation of comfort and pain felt with gloves for each hand</measure>
    <time_frame>At the end of each cycle (each cycle is 7 days)</time_frame>
    <description>Evaluation using a numeric scale from 0 (Very uncomfortable / Painful) to 10 (Very comfortable / No pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the ease to put on gloves for each hand</measure>
    <time_frame>At the end of paclitaxel administration (4 to 6 months)</time_frame>
    <description>Evaluation using a numeric scale from 0 (Very difficult / long) to 10 (Very easy / Fast)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort 1: Evaluation of the percentage of motor and sensitive peripheral neuropathies for each hand</measure>
    <time_frame>Before each cycle (except the 1st one), (each cycle is 7 days)</time_frame>
    <description>Evaluation using NPSI and MRC questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort 1: Evaluation of the percentage of motor and sensitive peripheral neuropathies for each hand</measure>
    <time_frame>At the end of paclitaxel administration (4 to 6 months after inclusion)</time_frame>
    <description>Evaluation using NPSI and MRC questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort 1: Evaluation of the percentage of motor and sensitive peripheral neuropathies for each hand</measure>
    <time_frame>12 months after the end of treatment</time_frame>
    <description>Evaluation using NPSI and MRC questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort 1: Evaluation of the percentage of peripheral neuropathies &gt;= 2 for each hand</measure>
    <time_frame>Before each cycle (except the 1st one) (each cycle is 7 days)</time_frame>
    <description>Evaluation using the NCI-CTCAE v5 scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort 1: Evaluation of the percentage of peripheral neuropathies &gt;= 2 for each hand</measure>
    <time_frame>At the end of paclitaxel administration (4 to 6 months after inclusion)</time_frame>
    <description>Evaluation using the NCI-CTCAE v5 scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort 1: Evaluation of the percentabe of onycholysis grade 2 for each hand</measure>
    <time_frame>At the end of paclitaxel administration (4 to 6 months after inclusion)</time_frame>
    <description>Evalutation using NCI-CTCAE v5 scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort 1: Evaluation of nurses's preference for the gloves wearing (surgical versus chilled gloves)</measure>
    <time_frame>At the end of paclitaxel administration (4 to 6 months after inclusion)</time_frame>
    <description>Evaluation using a numeric scale from 0 (Very xxxx) to 10 (Very xxxx)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort 2: Evaluation of the global satisfaction concerning surgical gloves wearing, comfort, pain and ease to wear</measure>
    <time_frame>At the end of oxaliplatine administration (4 to 6 months after inclusion)</time_frame>
    <description>Evaluation using a numeric scale from 0 (Very unsatisfied) to 10 (Very satisfied)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort 2: Evaluation of the acute sensitive peripheral neuropathies for each hand</measure>
    <time_frame>Before each cycle (except the 1st one) (each cycle is 7 days)</time_frame>
    <description>Evaluation using a duration questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort 2: Evaluation of the acute sensitive peripheral neuropathies for each hand</measure>
    <time_frame>At the end of oxaliplatine administration (4 to 6 months after inclusion)</time_frame>
    <description>Evaluation using a duration questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort 2: Evaluation of the peripheral neuropathies percentage for each hand</measure>
    <time_frame>After each cycle (except the 1st one), (each cycle is 7 days)</time_frame>
    <description>Evaluation using the NPSI questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort 2: Evaluation of the peripheral neuropathies percentage for each hand</measure>
    <time_frame>At the end of oxaliplatine administration (4 to 6 months after inclusion)</time_frame>
    <description>Evaluation using the NPSI questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort 2: Evaluation of the peripheral neuropathies percentage for each hand</measure>
    <time_frame>12 months after the end of treatment.</time_frame>
    <description>Evaluation using the NPSI questionnaire</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">151</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <description>Evaluation of patient's satisfaction when wearing surgical gloves (dominant hand) versus chilled gloves (non-dominant hand) at the end of paclitaxel administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <description>Evaluation of the efficacy of the compression induced by surgical gloves against peripheral neuropathies in patients treated by oxaliplatine after a 595 mg/m2 cumulated dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Chilled gloves</intervention_name>
    <description>Chilled glove for non-dominant hand (patients treated with paclitaxel)</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Surgical gloves</intervention_name>
    <description>Surgical gloves (patients treated with oxaliplatine)</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with adjuvant or metastatic:

          -  Breast cancer treated by Paclitaxel or,

          -  Colorectal cancer treated by Oxaliplatine
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;= 18 years old

          -  Breast cancer requiring a treatment by paclitaxel or colorectal cancer requiring a
             treatment by oxaliplatine

          -  At least 8 chemotherapy cycles planned

          -  Able to understand, read and write French language

          -  Covered by a social insurance

          -  Dated and signed informed consent

        Exclusion Criteria:

          -  Pre-existing neuropathy or history of neuropathy

          -  Psychological, family, sociological or georgraphical condition that may potentially
             compromise the adherence to study protocol and follow up

          -  Cohort 1: Patients presenting a Raynaud's syndrome (contra-indication to cold
             temperatures)

          -  Participation to clinical trial which may interfere with the evaluation of the main
             endpoints.

          -  Pregnant or breastfeeding women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas BACHELOT, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Leon Berard</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thomas BACHELOT, MD</last_name>
    <phone>+33 4.78.78.26.54</phone>
    <email>thomas.bachelot@lyon.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Aur√©lia CHABERT</last_name>
    <phone>+33 4.78.78.27.08</phone>
    <email>aurelia.joureau@lyon.unicancer.fr</email>
  </overall_contact_backup>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>March 8, 2019</study_first_submitted>
  <study_first_submitted_qc>March 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2019</study_first_posted>
  <last_update_submitted>May 27, 2019</last_update_submitted>
  <last_update_submitted_qc>May 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast cancer</keyword>
  <keyword>Colorectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

